Comparison

Ranibizumab European Partner

Manufacturer TargetMol
Category
Type Molecules
Specific against other
Amount 5mg
Item no. TMO-T9928-5mg
CASRN 347396-82-1
eClass 6.1 32169090
eClass 9.0 32169090
Available
Short Description
Ranibizumab is a humanized monoclonal antibody fragment designed to target and inhibit vascular endothelial growth factor (VEGF), including VEGF110, VEGF121, and VEGF165. Ranibizumab's ability to selectively target and neutralize VEGF-A isoforms has made it a crucial component of research and treatment strategies for wet wet age-related macular degeneration (AMD).
Shipping
cool pack
Storage
-20°
Molecular Weight
48 kDa
Pathway
Angiogenesis|||Tyrosine Kinase/Adaptors
Target
VEGFR

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 5mg
Available: In stock
available

Delivery expected until 4/18/2024 

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?